Once again, the miracle of nature known as aspirin gets some recognition. Studies done early in the COVID-19 pandemic (early 2020) suggested that non-steroid anti-inflammatory drugs (NSAID) may help reduce severity/lethality of COVID-19, however subsequent studies challenged those results and demonstrated worse outcomes in patients treated with NSAID. As more and more studies were done on the topic it now appears that aspirin is truly beneficial and reduces severity/lethality of COVID-19 while the most commonly used NSAID ibuprofen and acetominophen worsened severity/lethality. The only group where aspirin did not help was in people with pre-existing chronic inflammatory disorders (e.g. arthritis), which is probably due to the fact that such people are already in a very systemically inflamed state and in such people even mild COVID-19 can be deadly. The new findings suggests aspirin has unique effects not directly related to the simplistic “COX inhibition” that are responsible for its benefits. In all likelilhood, those additional effects are related to aspirin’s lipolysis inhibition effects as well as its ability to decrease lipid (PUFA) peroxidation, and inhibit fatty acid oxadation (FAO) – all of which have been shown to be relevant for COVID-19 pathology. If nine out of 10 COVID-19 deaths are due to vitamin D deficiency (as another recent blog post of mine discussed), and if aspirin drastically lowers the severity/lethality of COVID-19 (as another blog post also discussed) then we can save countless lives by simply administering these two dirt cheap, safe, widely available substances. Of course, such intervention is not nearly as “sexy” as selling “advanced” DNA modification therapies such as mRNA “vaccines”, so I doubt it will catch on.
“…Indomethacin and naproxen are among the NSAIDs which seem to directly antagonize SARS-CoV-2. Conversely, ibuprofen seemed to worsen clinical severity in a French study. The OpenSAFELY-based study from early in the pandemic, used data from 40% of English patients over 3.5 months in 2020. It showed that the use of NSAIDs within four months of March 1, 2020, did not increase COVID-19-related deaths in either of two groups: one with rheumatoid arthritis or osteoarthritis and one with a history of regular NSAID use within four months of the start of the study. Other small studies showed that aspirin use in patients within 24 days after admission, or seven days before admission, reduced both the severity and fatality rate of COVID-19.”
“…The odds ratios for increased severity of COVID-19 were highest with acetaminophen, at between 6-fold and 9-fold higher odds compared to non-users. In the cohort of non-survivors, these associations were equally significant.”